$1.04 Billion in Sales Expected for Nektar Therapeutics (NKTR) This Quarter

Analysts expect Nektar Therapeutics (NASDAQ:NKTR) to post $1.04 billion in sales for the current fiscal quarter, according to Zacks. Six analysts have made estimates for Nektar Therapeutics’ earnings. The highest sales estimate is $1.13 billion and the lowest is $1.02 billion. Nektar Therapeutics posted sales of $34.59 million during the same quarter last year, which suggests a positive year-over-year growth rate of 2,906.6%. The business is scheduled to report its next quarterly earnings report on Tuesday, August 14th.

According to Zacks, analysts expect that Nektar Therapeutics will report full-year sales of $1.15 billion for the current financial year, with estimates ranging from $1.10 billion to $1.24 billion. For the next fiscal year, analysts anticipate that the business will report sales of $249.92 million per share, with estimates ranging from $100.20 million to $528.34 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by ($0.08). Nektar Therapeutics had a negative return on equity of 202.41% and a negative net margin of 40.07%. The business had revenue of $38.02 million for the quarter, compared to the consensus estimate of $35.59 million. During the same quarter in the previous year, the company earned ($0.42) earnings per share. The firm’s revenue was up 53.7% on a year-over-year basis.

Several research analysts have issued reports on the stock. HC Wainwright set a $125.00 target price on shares of Nektar Therapeutics and gave the stock a “buy” rating in a report on Monday, May 14th. BidaskClub cut shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday. Mizuho increased their target price on shares of Nektar Therapeutics from $89.00 to $103.00 and gave the stock a “buy” rating in a report on Friday, April 6th. Finally, ValuEngine cut shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, June 26th. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Nektar Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $76.42.

In related news, SVP Stephen K. Doberstein sold 160,000 shares of Nektar Therapeutics stock in a transaction that occurred on Monday, April 9th. The shares were sold at an average price of $93.06, for a total value of $14,889,600.00. Following the completion of the sale, the senior vice president now directly owns 127,394 shares in the company, valued at approximately $11,855,285.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Howard W. Robin sold 130,000 shares of Nektar Therapeutics stock in a transaction that occurred on Thursday, May 3rd. The stock was sold at an average price of $84.05, for a total transaction of $10,926,500.00. Following the completion of the sale, the chief executive officer now owns 280,481 shares of the company’s stock, valued at $23,574,428.05. The disclosure for this sale can be found here. Insiders sold a total of 751,609 shares of company stock worth $59,177,957 over the last 90 days. Company insiders own 4.31% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in NKTR. Schroder Investment Management Group boosted its stake in Nektar Therapeutics by 90.9% in the 4th quarter. Schroder Investment Management Group now owns 14,016 shares of the biopharmaceutical company’s stock worth $837,000 after purchasing an additional 6,675 shares in the last quarter. Amalgamated Bank raised its position in Nektar Therapeutics by 6.3% during the 4th quarter. Amalgamated Bank now owns 21,775 shares of the biopharmaceutical company’s stock worth $1,300,000 after buying an additional 1,298 shares during the last quarter. Geode Capital Management LLC raised its position in Nektar Therapeutics by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 1,445,971 shares of the biopharmaceutical company’s stock worth $86,353,000 after buying an additional 13,958 shares during the last quarter. Alliancebernstein L.P. raised its position in Nektar Therapeutics by 14.0% during the 4th quarter. Alliancebernstein L.P. now owns 263,506 shares of the biopharmaceutical company’s stock worth $15,737,000 after buying an additional 32,269 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. purchased a new position in Nektar Therapeutics during the 4th quarter worth approximately $11,293,000. Institutional investors own 90.76% of the company’s stock.

Nektar Therapeutics stock traded down $0.02 during midday trading on Friday, hitting $48.83. 3,091,300 shares of the company’s stock were exchanged, compared to its average volume of 3,815,424. The company has a debt-to-equity ratio of 4.21, a current ratio of 4.16 and a quick ratio of 4.03. Nektar Therapeutics has a 12 month low of $17.51 and a 12 month high of $111.36. The stock has a market cap of $8.37 billion, a price-to-earnings ratio of -88.78 and a beta of 1.97.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain based on its PEGylation and polymer conjugate technology platforms in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply